Citizens Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $95 Price Target

Benzinga Newsdesk www.benzinga.com Negative 85.9%

Neg 85.9% Neu 0% Pos 0%

Citizens analyst Jonathan Wolleben reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and maintains $95 price target.